Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H; Japan Oncology Network in Hepatobiliary and Pancreas. Imaoka H, et al. Among authors: negoro y. J Gastroenterol. 2024 Nov 30. doi: 10.1007/s00535-024-02186-9. Online ahead of print. J Gastroenterol. 2024. PMID: 39614927
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y, Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y, Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N. Aoki M, et al. Among authors: negoro y. Gastric Cancer. 2023 Jan;26(1):132-144. doi: 10.1007/s10120-022-01349-y. Epub 2022 Nov 1. Gastric Cancer. 2023. PMID: 36316527 Free PMC article.
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, Manaka D, Negoro Y, Tsuji A, Takahashi T, Kochi M, Azuma M, Kadowaki S, Michimae H, Sunakawa Y, Ichikawa W, Fujii M. Kawabata R, et al. Among authors: negoro y. Target Oncol. 2023 May;18(3):359-368. doi: 10.1007/s11523-023-00961-x. Epub 2023 Apr 15. Target Oncol. 2023. PMID: 37060430 Clinical Trial.
Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study.
Negoro Y, Maeda T, Igarashi H, Shigemori M, Tanaka T, Ito Y, Tanizawa N, Nishikawa S, Ogawa J, Kamitani Y, Watanabe K, Tsukamoto H, Goto N. Negoro Y, et al. Support Care Cancer. 2024 Oct 7;32(10):704. doi: 10.1007/s00520-024-08910-8. Support Care Cancer. 2024. PMID: 39370483 Free PMC article.
Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
Tokuda PJK, Mitsuyoshi T, Ono Y, Kishi T, Negoro Y, Okumura S, Ikeda I, Sakamoto T, Kokubo Y, Ashida R, Imagumbai T, Yamashita M, Tanabe H, Takebe S, Tokiwa M, Suzuki E, Yamauchi C, Yoshimura M, Mizowaki T, Kokubo M; Kyoto Radiation Oncology Study Group. Tokuda PJK, et al. Among authors: negoro y. Breast Cancer. 2024 Jul;31(4):643-648. doi: 10.1007/s12282-024-01577-3. Epub 2024 Apr 12. Breast Cancer. 2024. PMID: 38607499 Free PMC article. Clinical Trial.
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Dote S, Shiwaku E, Kohno E, Fujii R, Mashimo K, Morimoto N, Yoshino M, Odaira N, Ikesue H, Hirabatake M, Takahashi K, Takahashi M, Takagi M, Nishiuma S, Ito K, Shimato A, Itakura S, Takahashi Y, Negoro Y, Shigemori M, Watanabe H, Hayasaka D, Nakao M, Tasaka M, Goto E, Kataoka N, Yokomizo A, Kobayashi A, Nakata Y, Miyake M, Hayashi Y, Yamamoto Y, Hirata T, Azuma K, Makihara K, Fukui R, Tokutome A, Yagisawa K, Honda S, Meguro Y, Suzuki S, Yamaguchi D, Miyata H, Kobayashi Y; IMBERA Investigators. Dote S, et al. Among authors: negoro y. Int J Clin Oncol. 2023 Aug;28(8):1054-1062. doi: 10.1007/s10147-023-02357-3. Epub 2023 Jun 1. Int J Clin Oncol. 2023. PMID: 37261583 Free PMC article.
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
Yamaguchi K, Minashi K, Sakai D, Nishina T, Omuro Y, Tsuda M, Iwagami S, Kawakami H, Esaki T, Sugimoto N, Oshima T, Kato K, Amagai K, Hosaka H, Komine K, Yasui H, Negoro Y, Ishido K, Tsushima T, Han S, Shiratori S, Takami T, Shitara K. Yamaguchi K, et al. Among authors: negoro y. Cancer Sci. 2022 Aug;113(8):2814-2827. doi: 10.1111/cas.15462. Epub 2022 Jul 1. Cancer Sci. 2022. PMID: 35701865 Free PMC article. Clinical Trial.
95 results